Recombinant Human IL3RA protein, His-tagged

• Cat.No.: IL3RA-3178H
• Product Overview: Recombinant Human IL3RA Protein(P26951-1)(Thr19-Arg305) is expressed from HEK293 with His tag at the C-Terminus.

Specification

• Source: HEK293
• Species: Human
• Tag: His
• Protein length: Met1-Arg305
• Form: Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
• Bio-activity: Immobilized Human IL-3 R alpha, His Tag at 0.5μg/ml (100μl/Well) on the plate. Dose response curve for Anti-IL-3 R alpha Antibody, hFc Tag with the EC50 of 13.3ng/ml determined by ELISA.
• Molecular Mass: The protein has a predicted MW of 33.9 kDa. Due to glycosylation, the protein migrates to 60-70 kDa based on Tris-Bis PAGE result.
• Endotoxin: Less than 1EU per μg by the LAL method.
• Purity: > 95% as determined by Tris-Bis PAGE
• Storage: -20 to -80°C for 12 months as supplied from date of receipt.
  -80°C for 3-6 months after reconstitution.
  2-8°C for 2-7 days after reconstitution.
  Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
• Reconstitution: Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.

Gene Information

• Gene Name: IL3RA interleukin 3 receptor, alpha (low affinity) [ Homo sapiens ]
• Official Symbol: IL3RA
• Synonyms: IL3RA; interleukin 3 receptor, alpha (low affinity); interleukin-3 receptor subunit alpha; CD123; IL-3RA; IL-3R-alpha; CD123 antigen; IL-3R subunit alpha; IL-3 receptor subunit alpha; IL-3 receptor alpha SP2 isoform; IL3R; IL3RX; IL3RY; IL3RAY; hIL-3Ra; MGC34174
• Gene ID: 3563
• mRNA Refseq: NM_002183
• Protein Refseq: NP_002174
• MIM: 308385
• UniProt ID: P26951

Reviews

07/24/2022

In special environment, good stability.

05/25/2022

Good crystallization property and good effect.

06/29/2021

Has the expected biological activity, such as enzyme activity and receptor binding activity, and so on.

Q&As

Can Il3ra be personalized?

The feasibility of personalized therapy depends on the specific disease type and patient situation, and more research is needed to determine the application of personalized therapy to Il3ra.

Does Il3ra have clinical application prospects? What are the prospects?

Il3ra has certain promise in clinical application, especially in the treatment of immune-related diseases.

What is the action mechanism of Il3ra?

Regulates the proliferation and differentiation of immune cells by binding to its interacting cytokine IL-3, and plays a role in regulating the function of the immune system.

How is the clinical trial of Il3ra progressing?

Clinical trials of recombinant Il3ra have been conducted in different disease areas. At present, some early trials show its potential in the treatment of certain diseases, but more research is needed to verify its efficacy and safety.

What is the specific effect of Il3ra on the immune system?

The Il3ra can regulate the proliferation and differentiation of different types of immune cells in the immune system, thus affecting the function of the immune system.

Does Il3ra have side effects?

Il3ra is generally well tolerated, but some minor side effects such as headache and nausea may occur. Serious side effects are rare.